Survival analysis of high-intensity focused ultrasound therapy vs. transarterial chemoembolization for unresectable hepatocellular carcinomas

Liver International

Volumn 34, Issue 6, 2014, Pages

  Cheung, Tan To ^a   Poon, Ronnie T P ^a   Jenkins, Caroline R ^a   Chu, Ferdinand S K ^a   Chok, Kenneth S H ^a   Chan, Albert C Y ^a   Tsang, Simon H Y ^a   Dai, Wing Chiu ^a   Yau, Thomas C C ^a   Chan, See Ching ^a   Fan, Sheung Tat ^a   Lo, Chung Mau ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

HCC; HIFU; Liver cancer; Morbidity; Mortality; Non invasive treatment; Survival

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CISPLATIN; IODINATED POPPYSEED OIL;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SIZE; CANCER SURVIVAL; CANCER THERAPY; CHEMOEMBOLIZATION; CONTROLLED STUDY; EVALUATION STUDY; FEMALE; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; LONG TERM CARE; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; SHORT COURSE THERAPY; TRANSARTERIAL CHEMOEMBOLIZATION; ULTRASOUND SCANNER; CARCINOMA, HEPATOCELLULAR; COMPARATIVE STUDY; DISEASE COURSE; HONG KONG; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; RISK FACTOR; TIME; TREATMENT OUTCOME; TUMOR VOLUME; VASCULARIZATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; DISEASE PROGRESSION; FEMALE; HIGH-INTENSITY FOCUSED ULTRASOUND ABLATION; HONG KONG; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84902553421     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12474     Document Type: Article

References (32)

1. Akriviadis EA, Llovet JM, Efremidis SC, et al. Hepatocellular carcinoma. Br J Surg 1998; 85: 1319-31.
2. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. study of 850 patients. Cancer 1985; 56: 918-28.
3. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-9.
4. Fan ST, Poon RT, Yeung C, et al. Outcome after partial hepatectomy for hepatocellular cancer within the milan criteria. Br J Surg 2011; 98: 1292-300.
5. Hasegawa K, Kokudo N, Makuuchi M, et al. Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey. J Hepatol 2013; 58: 724-9.
6. Lam CM, Ng KK, Poon RT, et al. Impact of radiofrequency ablation on the management of patients with hepatocellular carcinoma in a specialized centre. Br J Surg 2004; 91: 334-8.
7. Toshikuni N, Takuma Y, Goto T, Yamamoto H. Prognostic factors in hepatitis c patients with a single small hepatocellular carcinoma after radiofrequency ablation. Hepatogastroenterology 2012; 59: 2361-6.
8. Cheung TT, Ng KK, Poon RT, Fan ST. Tolerance of radiofrequency ablation by patients of hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 2009; 16: 655-60.
9. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-9.
10. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-71.
11. Doffoel M, Bonnetain F, Bouche O, et al. Multicentre randomised phase III trial comparing tamoxifen alone or with transarterial lipiodol chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Federation francophone de cancerologie digestive 9402). Eur J Cancer 2008; 44: 528-38.
12. Wu F. Extracorporeal high intensity focused ultrasound in the treatment of patients with solid malignancy. Minim Invasive Ther Allied Technol 2006; 15: 26-35.
13. Ng KK, Poon RT, Chan SC, et al. High-intensity focused ultrasound for hepatocellular carcinoma: a single-center experience. Ann Surg 2011; 253: 981-7.
14. Cheung TT, Fan ST, Chu FS, et al. Survival analysis of high-intensity focused ultrasound ablation in patients with small hepatocellular carcinoma. HPB 2013; 15: 567-73.
15. Yau T, Yao TJ, Chan P, et al. The outcomes of elderly patients with hepatocellular carcinoma treated with transarterial chemoembolization. Cancer 2009; 115: 5507-15.
16. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.
17. Lo CM. Deceased donation in Asia: challenges and opportunities. Liver Transpl 2012; 18(Suppl.2): S5-7.
18. Busuttil RW, Farmer DG, Yersiz H, et al. Analysis of long-term outcomes of 3200 liver transplantations over two decades: a single-center experience. Ann Surg 2005; 241: 905-16.
19. Lee SG, Hwang S, Kim KH, et al. Toward 300 liver transplants a year. Surg Today 2009; 39: 367-73.
20. Lo CM, Fan ST, Liu CL, et al. Ten-year experience with liver transplantation at queen mary hospital: retrospective study. Hong Kong Med J 2002; 8: 240-4.
21. Yong CC, Chen YS, Wang SH, et al. Deceased-donor liver transplantation: 10 years' experience at change gung memorial hospital-kaohsiung medical center. Chang Gung Med J 2005; 28: 133-41.
22. Forner A, Llovet JM, Bruix J. Chemoembolization for intermediate HCC: is there proof of survival benefit? J Hepatol 2012; 56: 984-6.
23. Bruix J, Raoul JL, Sherman M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase iii trial. J Hepatol 2012; 57: 821-9.
24. Iavarone M, Cabibbo G, Piscaglia F, et al. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology 2011; 54: 2055-63.
25. Koeberle D, Montemurro M, Samaras P, et al. Continuous sunitinib treatment in patients with advanced hepatocellular carcinoma: a swiss group for clinical cancer research (SAKK) and swiss association for the study of the liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist 2010; 15: 285-92.
26. Chung YH, Han G, Yoon JH, et al. Interim analysis of START: study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial. Int J Cancer 2013; 132: 2448-58.
27. Song MJ, Chun HJ, Song DS, et al. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol 2012; 57: 1244-50.
28. Chan AC, Cheung TT, Fan ST, et al. Survival analysis of high-intensity focused ultrasound therapy versus radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma. Ann Surg 2013; 257: 686-92.
29. Cheung TT, Chu FS, Jenkins CR, et al. Tolerance of high-intensity focused ultrasound ablation in patients with hepatocellular carcinoma. World J Surg 2012; 36: 2420-7.
30. Cheung TT, Poon RT, Yau T, et al. High-intensity focused ultrasound as a treatment for colorectal liver metastasis in difficult position. Int J Colorectal Dis 2012; 27: 987-8.
31. Li JX, Wu H, Huang JW, Zeng Y. The influence on liver function after transcatheter arterial chemoembolization combined with percutaneous radiofrequency ablation in patients with hepatocellular carcinoma. J Formos Med Assoc 2012; 111: 510-5.
32. Cheung TT, Chok KS, Lo RC, et al. High-intensity focused ultrasound ablation as a bridging therapy for hepatocellular carcinoma patients awaiting liver transplantation. Hepatobiliary Pancreat Dis Int 2012; 11: 542-4.